Pfizer (NYSE:PFE) Issues FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus EPS estimate of 2.970. The company issued revenue guidance of $59.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.3 billion.

Pfizer Trading Down 0.1%

NYSE PFE opened at $26.31 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm’s fifty day moving average price is $27.17 and its 200 day moving average price is $26.11. The company has a market capitalization of $149.61 billion, a price-to-earnings ratio of 19.35 and a beta of 0.35. Pfizer has a 12 month low of $21.97 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is presently 126.47%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. HSBC boosted their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.74.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported strong first-quarter results and reaffirmed its full?year 2026 guidance, with CEO Albert Bourla highlighting R&D progress and pipeline momentum — a direct support for near?term revenue visibility and investor confidence. Read More.
• Positive Sentiment: Q1 profit topped Wall Street estimates, helped by sustained demand for legacy drug Eliquis — showing Pfizer can still drive cash flow from established franchises even as it builds newer growth drivers. Read More.
• Positive Sentiment: Pfizer and Arvinas won FDA approval for VEPPANU (vepdegestrant), a first?of?its?kind therapy for ESR1?mutated advanced breast cancer — a meaningful commercial and strategic win for Pfizer’s oncology portfolio. Read More.
• Neutral Sentiment: Analysts remain generally bullish on Pfizer’s pipeline (including obesity opportunities); investors will watch management commentary on pipeline timelines and guidance as catalysts. Read More.
• Neutral Sentiment: Pre?market coverage flagged Pfizer among stocks to watch and dividend?oriented trade ideas; the company’s high yield attracts income investors even as growth questions persist. Read More.
• Negative Sentiment: Commentary from TV and opinion sources questions whether Pfizer’s dividend is compelling versus fixed?income alternatives (e.g., “If I want good yield, I’ll buy a bond”), a narrative that can pressure income?sensitive holders and mute upside. Read More.
• Negative Sentiment: Longer?term critiques (e.g., “priced like dead money”) highlight investor concerns about secular growth prospects and valuation, which can cap multiple expansion despite strong cash generation. Read More.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Darwin Wealth Management LLC purchased a new stake in Pfizer in the 2nd quarter worth approximately $32,000. IFC & Insurance Marketing Inc. purchased a new stake in Pfizer in the 4th quarter worth approximately $34,000. Birchwood Financial Partners Inc. purchased a new stake in Pfizer in the 4th quarter worth approximately $38,000. WFA of San Diego LLC purchased a new stake in Pfizer in the 2nd quarter worth approximately $40,000. Finally, Atlas Capital Advisors Inc. purchased a new stake in Pfizer in the 4th quarter worth approximately $41,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.